Characteristic MicroRNAs Linked to Dysregulated Metabolic Pathways in Qatari Adult Subjects With Obesity and Metabolic Syndrome.
HbA1c
metabolic disorder
miRNA
mirDIP
network analysis
obesity
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
05
05
2022
accepted:
24
06
2022
entrez:
8
8
2022
pubmed:
9
8
2022
medline:
10
8
2022
Statut:
epublish
Résumé
Obesity-associated dysglycemia is associated with metabolic disorders. MicroRNAs (miRNAs) are known regulators of metabolic homeostasis. We aimed to assess the relationship of circulating miRNAs with clinical features in obese Qatari individuals. We analyzed a dataset of 39 age-matched patients that includes 18 subjects with obesity only (OBO) and 21 subjects with obesity and metabolic syndrome (OBM). We measured 754 well-characterized human microRNAs (miRNAs) and identified differentially expressed miRNAs along with their significant associations with clinical markers in these patients. A total of 64 miRNAs were differentially expressed between metabolically healthy obese (OBO) versus metabolically unhealthy obese (OBM) patients. Thirteen out of 64 miRNAs significantly correlated with at least one clinical trait of the metabolic syndrome. Six out of the thirteen demonstrated significant association with HbA1c levels; miR-331-3p, miR-452-3p, and miR-485-5p were over-expressed, whereas miR-153-3p, miR-182-5p, and miR-433-3p were under-expressed in the OBM patients with elevated HbA1c levels. We also identified, miR-106b-3p, miR-652-3p, and miR-93-5p that showed a significant association with creatinine; miR-130b-5p, miR-363-3p, and miR-636 were significantly associated with cholesterol, whereas miR-130a-3p was significantly associated with LDL. Additionally, miR-652-3p's differential expression correlated significantly with HDL and creatinine. MicroRNAs associated with metabolic syndrome in obese subjects may have a pathophysiologic role and can serve as markers for obese individuals predisposed to various metabolic diseases like diabetes.
Sections du résumé
Background
Obesity-associated dysglycemia is associated with metabolic disorders. MicroRNAs (miRNAs) are known regulators of metabolic homeostasis. We aimed to assess the relationship of circulating miRNAs with clinical features in obese Qatari individuals.
Methods
We analyzed a dataset of 39 age-matched patients that includes 18 subjects with obesity only (OBO) and 21 subjects with obesity and metabolic syndrome (OBM). We measured 754 well-characterized human microRNAs (miRNAs) and identified differentially expressed miRNAs along with their significant associations with clinical markers in these patients.
Results
A total of 64 miRNAs were differentially expressed between metabolically healthy obese (OBO) versus metabolically unhealthy obese (OBM) patients. Thirteen out of 64 miRNAs significantly correlated with at least one clinical trait of the metabolic syndrome. Six out of the thirteen demonstrated significant association with HbA1c levels; miR-331-3p, miR-452-3p, and miR-485-5p were over-expressed, whereas miR-153-3p, miR-182-5p, and miR-433-3p were under-expressed in the OBM patients with elevated HbA1c levels. We also identified, miR-106b-3p, miR-652-3p, and miR-93-5p that showed a significant association with creatinine; miR-130b-5p, miR-363-3p, and miR-636 were significantly associated with cholesterol, whereas miR-130a-3p was significantly associated with LDL. Additionally, miR-652-3p's differential expression correlated significantly with HDL and creatinine.
Conclusions
MicroRNAs associated with metabolic syndrome in obese subjects may have a pathophysiologic role and can serve as markers for obese individuals predisposed to various metabolic diseases like diabetes.
Identifiants
pubmed: 35937842
doi: 10.3389/fendo.2022.937089
pmc: PMC9352892
doi:
Substances chimiques
Biomarkers
0
Glycated Hemoglobin A
0
MIRN153 microRNA, human
0
MIRN363 microRNA, human
0
MIRN433 microRNA, human
0
MIRN485 microRNA, human
0
MicroRNAs
0
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
937089Informations de copyright
Copyright © 2022 Mir, Mall, Iskandarani, Ullah, Samra, Cyprian, Parray, Alkasem, Abdalhakam, Farooq and Abou-Samra.
Déclaration de conflit d'intérêts
Authors FM, AI, TS, AP, MA, IA, and A-BA-S were employed by HMC. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Physiol. 2022 Mar;600(5):1155-1169
pubmed: 34392542
Methods Enzymol. 2006;411:14-34
pubmed: 16939783
Am J Clin Nutr. 2019 Sep 1;110(3):533-539
pubmed: 31240297
Obes Rev. 2014 Oct;15(10):781-90
pubmed: 25040597
Int J Obes (Lond). 2021 May;45(5):934-943
pubmed: 33510393
Nat Rev Nephrol. 2021 May;17(5):319-334
pubmed: 33547417
J Clin Endocrinol Metab. 2012 Dec;97(12):E2271-6
pubmed: 23032062
Int J Mol Med. 2017 Jul;40(1):83-89
pubmed: 28535002
Stem Cell Investig. 2017 Apr 14;4:28
pubmed: 28529943
J Immunol Res. 2014;2014:987285
pubmed: 24741638
Nucleic Acids Res. 2018 Apr 20;46(7):e39
pubmed: 29361062
Lancet Diabetes Endocrinol. 2020 Jun;8(6):477-489
pubmed: 32445735
Front Genet. 2021 Sep 08;12:702410
pubmed: 34567065
J Physiol Biochem. 2018 May;74(2):291-299
pubmed: 29470815
BMC Endocr Disord. 2014 Feb 01;14:9
pubmed: 24484869
Am J Clin Nutr. 1956 Jan-Feb;4(1):20-34
pubmed: 13282851
BMC Cardiovasc Disord. 2021 Mar 24;21(1):150
pubmed: 33761890
NPJ Breast Cancer. 2021 Feb 8;7(1):10
pubmed: 33558495
Cells. 2020 Jul 13;9(7):
pubmed: 32668665
PLoS One. 2014 Sep 19;9(9):e107986
pubmed: 25238238
Int J Mol Sci. 2022 Jan 12;23(2):
pubmed: 35054972
Obes Rev. 2019 May;20(5):648-658
pubmed: 30609449
PLoS One. 2013 Oct 15;8(10):e77251
pubmed: 24204780
Sci Rep. 2017 Mar 23;7:44986
pubmed: 28332581
Arch Intern Med. 2008 Aug 11;168(15):1609-16
pubmed: 18695074
J Clin Endocrinol Metab. 2006 Aug;91(8):2906-12
pubmed: 16735483
Cell Metab. 2017 Aug 1;26(2):292-300
pubmed: 28768170
Am J Physiol Endocrinol Metab. 2017 Jun 1;312(6):E482-E494
pubmed: 28270439
J Immunother Cancer. 2020 Apr;8(1):
pubmed: 32376723
Nanoscale. 2022 Jan 6;14(2):333-349
pubmed: 34796889
BMC Genomics. 2009 Aug 28;10:407
pubmed: 19715577
Diabetes. 2009 Nov;58(11):2555-64
pubmed: 19720801
Eur J Heart Fail. 2016 Aug;18(8):1000-8
pubmed: 27072074
Clin Nutr. 2020 Mar;39(3):910-916
pubmed: 31003790
Nat Protoc. 2016 Oct;11(10):1889-907
pubmed: 27606777
PLoS One. 2017 Nov 14;12(11):e0187973
pubmed: 29136041
J Endocrinol. 2014 Jul;222(1):R1-R10
pubmed: 24781254
Arch Intern Med. 2007 Apr 9;167(7):642-8
pubmed: 17420421
Nat Rev Mol Cell Biol. 2012 Mar 22;13(4):239-50
pubmed: 22436747
Oncotarget. 2017 Oct 16;8(63):106844-106857
pubmed: 29290993
Clin Lab. 2021 Feb 1;67(2):
pubmed: 33616325
Diabetes Care. 2014;37(5):1375-83
pubmed: 24478399
Diabetes Care. 2017 Apr;40(4):546-553
pubmed: 28183786
Endocr Rev. 2020 May 1;41(3):
pubmed: 32128581
J Clin Lab Anal. 2021 Sep;35(9):e23945
pubmed: 34398996
Nat Rev Endocrinol. 2019 Dec;15(12):731-743
pubmed: 31611648
J Clin Endocrinol Metab. 2020 Mar 1;105(3):
pubmed: 31730174
Diabet Med. 2015 May;32(5):665-72
pubmed: 25438871
Clin Exp Pharmacol Physiol. 2019 Dec;46(12):1092-1100
pubmed: 31355469
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Brief Bioinform. 2021 Nov 5;22(6):
pubmed: 33979427
Biochem Biophys Res Commun. 2018 Sep 10;503(3):1503-1509
pubmed: 30029881
Sci Rep. 2016 Apr 18;6:23476
pubmed: 27087055
Cancer Biomark. 2019;26(4):501-512
pubmed: 31658041
J Cell Biochem. 2018 Nov;119(10):8623-8635
pubmed: 30058740
Nat Rev Gastroenterol Hepatol. 2013 Sep;10(9):542-52
pubmed: 23689081